{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=13", "query": { "intervention": "Radiotherapy followed by chemotherapy", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 887, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T18:21:51.844Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00899847", "title": "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplantation, Homologous", "Transplantation, Autologous", "Multiple Myeloma", "Blood and Marrow Transplant (BMT)" ], "interventions": [ { "name": "Autologous peripheral blood stem cells (auto-PBSC) transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic peripheral blood stem cells (allo-PBSC) transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Total lymphoid irradiation", "type": "RADIATION" }, { "name": "Rabbit anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Mycophenolate Mofetil 250mg", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 9, "start_date": "2009-05", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899847" }, { "nct_id": "NCT01262560", "title": "Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dysphagia", "Lung Cancer", "Pain", "Esophagitis" ], "interventions": [ { "name": "Manuka honey in liquid form", "type": "DRUG" }, { "name": "Manuka honey in lozenge form", "type": "DRUG" }, { "name": "Standard supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2012-02", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2017-08-31", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 59, "location_summary": "Mobile, Alabama • San Francisco, California • Stanford, California + 50 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262560" }, { "nct_id": "NCT05192889", "title": "Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Acute Lymphoblastic Leukemia", "Relapsed Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Intrathecal Triples", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "4 Years to 30 Years" }, "enrollment_count": 35, "start_date": "2022-08-25", "completion_date": "2027-02", "has_results": true, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 2, "location_summary": "New York, New York • Memphis, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05192889" }, { "nct_id": "NCT03939689", "title": "I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer", "Castration-resistant Prostate Cancer", "Prostatic Neoplasm", "Cancer of the Prostate", "Progressive mCRPC" ], "interventions": [ { "name": "I-131-1095", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Progenics Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2019-05-30", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 20, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03939689" }, { "nct_id": "NCT05894083", "title": "A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Cancer", "Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Chemoradiation", "type": "COMBINATION_PRODUCT" }, { "name": "Observation", "type": "OTHER" }, { "name": "Post-operative radiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "COMBINATION_PRODUCT", "OTHER", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2023-04-27", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05894083" }, { "nct_id": "NCT04523818", "title": "Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage IIA Gastric Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Gastric Adenocarcinoma", "Pathologic Stage IB Gastric Cancer AJCC v8", "Pathologic Stage II Gastric Cancer AJCC v8", "Pathologic Stage IIA Gastric Cancer AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-08-11", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04523818" }, { "nct_id": "NCT00003935", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumors", "Central Nervous System Tumors" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 31, "start_date": "1999-09", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2014-07-28", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 97, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003935" }, { "nct_id": "NCT03725059", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab (K)", "type": "BIOLOGICAL" }, { "name": "Placebo (P)", "type": "DRUG" }, { "name": "Paclitaxel (X)", "type": "DRUG" }, { "name": "Doxorubicin (A)", "type": "DRUG" }, { "name": "Epirubicin (E)", "type": "DRUG" }, { "name": "Cyclophosphamide (C)", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1240, "start_date": "2018-12-27", "completion_date": "2031-01-24", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 45, "location_summary": "Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03725059" }, { "nct_id": "NCT00033696", "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 65, "start_date": "2001-09", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2016-07-19", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 51, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033696" }, { "nct_id": "NCT03307785", "title": "Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Metastatic Cancer", "Advanced Cancer", "Solid Tumor", "Non Small Cell Lung Cancer Metastatic", "Non Small Cell Lung Cancer Stage IIIB", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "Carboplatin-Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TSR-022", "type": "DRUG" }, { "name": "Carboplatin-Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin-Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-10-12", "completion_date": "2024-12-11", "has_results": true, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-14T18:21:51.844Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03307785" } ] }